Wyeth Says Bifeprunox Side Effect Profile Is Benefit Over Atypical Antipsychotics
This article was originally published in The Pink Sheet Daily
Executive Summary
NDA submission buoyed by four Phase III studies, including two involving active comparators.
You may also be interested in...
Wyeth Ends Bifeprunox For Schizophrenia Development Deal With Solvay
Wyeth decides drug candidate has inadequate commercial value for both companies to share, firm tells "The Pink Sheet" DAILY.
Wyeth Ends Bifeprunox For Schizophrenia Development Deal With Solvay
Wyeth decides drug candidate has inadequate commercial value for both companies to share, firm tells "The Pink Sheet" DAILY.
Wyeth Will Pursue Maintenance Indication For Bifeprunox; Acute Treatment Is Unclear
FDA’s “not approvable” decision for both claims could set the antipsychotic’s potential approval timeframe back two years.